 |
52 Diseases |  |
106 Trials |
|
106 Trials |  |
1305 News |  |
| «12...11121314151617181920212223» |
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Jun 11, 2015
P2, N=300, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: May 2015 --> Jan 2018
- Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial primary completion date: Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma (clinicaltrials.gov) - Jun 11, 2015
P1, N=33, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: May 2015 --> Jan 2018 Trial primary completion date: Jun 2015 --> Sep 2015
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Jun 11, 2015
P2, N=300, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2015 --> Sep 2015 Recruiting --> Suspended
- Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment change: Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Jun 11, 2015
P1, N=24, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended N=20 --> 24
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open: NCI-2015-00960: Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov) - Jun 6, 2015
P2, N=50, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=20 --> 24 Not yet recruiting --> Recruiting
- | Keytruda (pembrolizumab) / Merck (MSD), Rituxan (rituximab) / Roche
New P2 trial, PD(L)-1 Biomarker: Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - May 19, 2015
P2, N=30, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment closed: Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma (clinicaltrials.gov) - May 19, 2015
P1, N=33, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Suspended --> Active, not recruiting
- ||||| Jakafi oral (ruxolitinib) / Novartis, Incyte, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 8, 2015
P2, N=92, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- ||| Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku
Trial completion: Demonstrate the Equivalence of CT-P10 to MabThera With Respect to the Pharmacokinetic Profile in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - May 8, 2015
P1, N=154, Completed, Sponsor: Celltrion
Suspended --> Active, not recruiting Active, not recruiting --> Completed
- Kepivance (palifermin) / SOBI, Amgen
Enrollment open: Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (clinicaltrials.gov) - May 5, 2015
P1/2, N=50, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
New P2 trial: NCI-2015-00960: Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov) - Apr 30, 2015
P2, N=50, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- ||||| Jakafi oral (ruxolitinib) / Novartis, Incyte, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 20, 2015
P2, N=80, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- Rituxan (rituximab) / Roche, Yervoy (ipilimumab) / BMS
Trial primary completion date: Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) - Apr 14, 2015
P1, N=38, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2015 --> Apr 2016
- Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial primary completion date: Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma (clinicaltrials.gov) - Mar 9, 2015
P1, N=33, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Apr 2015 --> Apr 2016 Trial primary completion date: Dec 2014 --> Jun 2015
- Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial primary completion date: High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma (clinicaltrials.gov) - Mar 7, 2015
P2, N=24, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Dec 2014 --> Jun 2015 Trial primary completion date: Nov 2014 --> Nov 2015
- |||||| Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Enrollment open, IO biomarker: Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma (clinicaltrials.gov) - Feb 24, 2015
P3, N=128, Recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Nov 2014 --> Nov 2015 Not yet recruiting --> Recruiting
- || Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 5, 2015
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2015 --> Oct 2016
- Kepivance (palifermin) / SOBI, Amgen
New P1/2 trial: Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (clinicaltrials.gov) - Feb 5, 2015
P1/2, N=50, Recruiting, Sponsor: National Cancer Institute (NCI)
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Arzerra (ofatumumab) / Novartis, Genmab, Rituxan (rituximab) / Roche
Enrollment open: NCI-2014-01707: Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 18, 2015
P2, N=40, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Oct 2015 --> Oct 2016 Not yet recruiting --> Recruiting
- | Ninlaro (ixazomib) / Takeda, Rituxan (rituximab) / Roche
New P2 trial: Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jan 17, 2015
P2, N=45, Not yet recruiting, Sponsor: University of Washington
- |||||||||| Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
New P3 trial, IO biomarker: Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma (clinicaltrials.gov) - Dec 19, 2014
P3, N=128, Not yet recruiting, Sponsor: Mayo Clinic
- Enrollment open: MPAL: Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia (clinicaltrials.gov) - Oct 30, 2014
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial primary completion date: High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma (clinicaltrials.gov) - Oct 22, 2014
P2, N=24, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2014 --> Nov 2014
- ||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Rituxan (rituximab) / Roche
Trial completion, Trial primary completion date: Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant (clinicaltrials.gov) - Oct 17, 2014
P1, N=60, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Apr 2014 --> Nov 2014 Active, not recruiting --> Completed | Trial primary completion date: Apr 2016 --> Oct 2014
- |||||||||| Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku
New P3 trial: To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma (clinicaltrials.gov) - Oct 10, 2014
P3, N=104, Not yet recruiting, Sponsor: Celltrion
- Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial suspension: Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma (clinicaltrials.gov) - Sep 22, 2014
P1, N=33, Suspended, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial primary completion date: Apr 2016 --> Oct 2014 Recruiting --> Suspended
- Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open, Trial primary completion date: Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Sep 22, 2014
P1, N=20, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2016 --> Mar 2018
- || Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Rituxan (rituximab) / Roche
Trial primary completion date: Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant (clinicaltrials.gov) - Sep 5, 2014
P1, N=60, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2016 --> Mar 2018 Trial primary completion date: Apr 2015 --> Apr 2016
- Torisel (temsirolimus) / Pfizer, Rituxan (rituximab) / Roche
Enrollment closed: Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma (clinicaltrials.gov) - Aug 21, 2014
P1/2, N=144, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Apr 2015 --> Apr 2016 Recruiting --> Active, not recruiting
- | Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku
Enrollment change: A study to investigate and compare the efficacy, safety, tolerability and pharmacodynamic (biochemical and physiological effects of the drug) of TL011 and MabThera (EUDRACT) - Aug 19, 2014
P3, N=544, Suspended, Sponsor: Teva Pharmaceutical Industries
Recruiting --> Active, not recruiting N=80 --> 544
- Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
New P1 trial: Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Aug 19, 2014
P1, N=20, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- |||||| Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku
Enrollment open, Combination therapy, Head-to-Head, Metastases: To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan (clinicaltrials.gov) - Aug 6, 2014
P3, N=250, Recruiting, Sponsor: Celltrion
N=80 --> 544 Not yet recruiting --> Recruiting
- |||||| Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku
Enrollment open: PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Aug 6, 2014
P3, N=300, Recruiting, Sponsor: Celltrion
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku
Enrollment closed: Long-Term Efficacy and Safety of CT-P10 in Patients With RA (clinicaltrials.gov) - Aug 6, 2014
P1, N=102, Active, not recruiting, Sponsor: Celltrion
Not yet recruiting --> Recruiting Enrolling by invitation --> Active, not recruiting
- |||| Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 1, 2014
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Recruiting
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Arzerra (ofatumumab) / Novartis, Genmab, Rituxan (rituximab) / Roche
New P2 trial: NCI-2014-01707: Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 24, 2014
P2, N=40, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku
Enrollment change, Trial termination, Trial primary completion date: Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial (clinicaltrials.gov) - Jul 23, 2014
P1, N=1, Terminated, Sponsor: Celltrion
Active, not recruiting --> Recruiting N=10 --> 1 | Recruiting --> Terminated | Trial primary completion date: Oct 2012 --> Feb 2013
- ||| Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku
Enrollment open: Demonstrate the Equivalence of CT-P10 to MabThera With Respect to the Pharmacokinetic Profile in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 23, 2014
P1, N=147, Recruiting, Sponsor: Celltrion
N=10 --> 1 | Recruiting --> Terminated | Trial primary completion date: Oct 2012 --> Feb 2013 Active, not recruiting --> Recruiting
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment closed: Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov) - Jul 16, 2014
P2, N=50, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial primary completion date: Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant (clinicaltrials.gov) - Jul 14, 2014
P2, N=52, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2015 --> Feb 2016
- || Rituxan (rituximab) / Roche
Trial primary completion date: NCI-2018-01853: Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jul 10, 2014
P2, N=155, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Feb 2015 --> Feb 2016 Trial primary completion date: Jun 2015 --> Jun 2016
- |||||||||| Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku
New P3 trial, Combination therapy, Head-to-Head, Metastases: To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan (clinicaltrials.gov) - Jun 13, 2014
P3, N=250, Not yet recruiting, Sponsor: Celltrion
- Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
New P1 trial: Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Jun 8, 2014
P1, N=28, Recruiting, Sponsor: National Cancer Institute (NCI)
- Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open: Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Jun 5, 2014
P1, N=28, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2015 --> Jun 2016 Not yet recruiting --> Recruiting
- |||||||||| Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku
New P3 trial: PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - May 22, 2014
P3, N=300, Not yet recruiting, Sponsor: Celltrion
- Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial primary completion date: Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma (clinicaltrials.gov) - May 18, 2014
P1, N=33, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2014 --> Dec 2014
- | New P2 trial: MPAL: Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia (clinicaltrials.gov) - May 8, 2014
P2, N=60, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- Rituxan (rituximab) / Roche
Trial primary completion date: Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma (clinicaltrials.gov) - May 1, 2014
P1/2, N=81, Recruiting, Sponsor: OHSU Knight Cancer Institute
Trial primary completion date: Jan 2014 --> Dec 2014 Trial primary completion date: Jan 2015 --> Jan 2016
- Rituxan (rituximab) / Roche
Trial completion date: Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma (clinicaltrials.gov) - May 1, 2014
P1/2, N=81, Recruiting, Sponsor: OHSU Knight Cancer Institute
Trial primary completion date: Jan 2015 --> Jan 2016 Trial completion date: Jan 2016 --> Jan 2017
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Apr 16, 2014
P1/2, N=73, Recruiting, Sponsor: Roswell Park Cancer Institute
Trial completion date: Jan 2016 --> Jan 2017 Not yet recruiting --> Recruiting